Novo Nordisk AS (LTS:0TDD) FFO


LTS:0TDD Novo Nordisk AS LTS:0TDD
83 GF Score
Price $48.23
GF Value $136.00
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0TDD
83GF Score
Novo Nordisk AS LTS:0TDD
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (LTS:0TDD) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of $48.23 is trading 64.5% below its estimated GF Value™ of $136.00. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for LTS:0TDD:

  • FFO:
  • GF Value™: $136.00 vs. price of $48.23 (64.5% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the LTS:0TDD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
83GF Score

Get the complete analysis for LTS:0TDD

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$48.23
Price
$136.00
GF Value